NICE draft guidance does not recommend Evrysdi for SMA 3rd June 2021 The UK National Institute for Health and Care Excellence (NICE) has announced that it does not recommend Roche’s Evrysdi for the treatment of spinal muscular atrophy (SMA) in draft guidance. Evrysdi (risdiplam) is licensed for the treatment of patients with types 1, 2 and 3 SMA in the EU. In a statement, NICE said that although clinical trials demonstrate that Roche’s drug meaningfully improves motor function for these patients, the long-term benefits are uncertain. The committee also added that the oral administration of Evrysdi is ‘innovative’, as it offers an alternative for patients who cannot receive other SMA treatments and allows for home administration.